Skip to content
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
SVB Securities Global Biopharma Conference
February 16, 2023
8:00 am
Publications
Click here for Webcast
READ MORE
September 8, 2025
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
Read More »
July 28, 2025
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Read More »
June 30, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Read More »
See all News
